Arthrites juvéniles idiopathiques
Veille bibliographique : AJI
Les articles sont classés du plus ancien au plus récent, n’hésitez pas à utiliser la barre de recherche pour filtrer les résultats par date par exemple.
| Al-Mayouf SM et al. Loss-of-function variant in DNASE1L3 causes a familial form of systemic lupus erythematosus. Nat Genet 2011;43:1186–8 Wakil SM et al.Mutation of LACC1 is associated with a Monogenic Form of Systemic Juvenile Idiopathic Arthritis. Arthritis Rheumatol Hoboken NJ 2014; De Benedetti F et al.Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2385–95. De Benedetti F et al.Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: Results from the TENDER trial. Arthritis Rheumatol Hoboken NJ 2014; | |
| Lovell DJ et al.Pediatric Rheumatology Collaborative Study Group (PRCSG); Paediatric Rheumatology International Trials Organization (PRINTO). Long-Term Safety, Efficacy, and Quality of Life with Intravenous Abatacept in Juvenile Idiopathic Arthritis: Up to 7 Years of Treatment. Arthritis Rheumatol. 2015 Jun 19 | |
| Put K et al.Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-γ. Rheumatology (Oxford). 2015 Aug;54(8):1507-17 | |
| Davies R et al.British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Medically Significant Infections Are Increased in Patients With Juvenile Idiopathic Arthritis Treated With Etanercept: Results From the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Arthritis Rheumatol. 2015 Sep | |
| Lin C-H et al.Epidemiology and risk of juvenile idiopathic arthritis among children with allergic diseases: a nationwide population-based study. Pediatr Rheumatol Online J. 10 mars 2016;14(1):15. | Lire le résumé |
| Ravelli A et al.2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol Hoboken NJ. mars 2016;68(3):566‑76. | |
| Armbrust W et al.Fatigue in patients with juvenile idiopathic arthritis: A systematic review of the literature. Semin Arthritis Rheum. avr 2016;45(5):587‑95 | |
| Pacharapakornpong T et al. Comparisons of the outcomesbetween early and late tocilizumab treatment in systemic juvenile idiopathic arthritis. Rheumatol Int. 31 oct 2016; | |
| Di Paola M et al.Alteration of Fecal Microbiota Profiles in Juvenile Idiopathic Arthritis. Associations with HLA-B27 Allele and Disease Status. Front Microbiol. 2016;7:1703. | |
| McErlane F et al.Trends in paediatric rheumatology referral times and disease activity indices over a ten-year period among children and young people with Juvenile Idiopathic Arthritis: results from the childhood arthritis prospective Study. Rheumatol Oxf Engl. juill 2016;55(7):1225‑34. | |
| Shoop-Worrall SJW et al. How common is clinically inactive disease in a prospective cohort of patients with juvenile idiopathic arthritis? The importance of definition. Ann Rheum Dis. 2017 Apr 7; | |
| Schulert GS et al. Biologic therapy modifies clinical and laboratory features of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis. Arthritis Care Res. 2017 May 12 | |
| Brunner HI et al. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. Ann Rheum Dis. 2017 May 15; | |
| Calvo-Río V et al. Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients. Arthritis Rheumatol Hoboken NJ. 2017 Mar;69(3):668–75. | |
| Alexeeva EI et al. Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of Children’s Health, Russia. Pediatr Rheumatol Online J. 2017 Jun 14;15(1):51 | |
| Ravelli A et al. Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial. Lancet Lond Engl. 2017 Mar 4;389(10072):909–16. | |
| Marasco E. Switched Memory B Cells Are Increased In Oligoarticular And Polyarticular Juvenile Idiopathic Arthritis And Their Change Over Time Is Related To Response To TNF Inhibitors. Arthritis Rheumatol. 2018 Jan 5. | Lire le résumé |
| Lovell DJ et al. Risk, Timing and Predictors of Disease Flare after Discontinuation of Anti-Tumor Necrosis Factor (TNF) Therapy in Children with Polyarticular Forms of Juvenile Idiopathic Arthritis (JIA) in Clinical Inactive Disease. Arthritis Rheumatol. 2018 Mar 31 | Lire le résumé |
| Goirand M et al. Clinical features of children with enthesitis-related juvenile idiopathic arthritis / juvenile spondyloarthritis followed in a French tertiary care pediatric rheumatology centre. Pediatr Rheumatol Online J. 2018 Apr 2 | Lire le résumé |
| Schulert GS, Minoia F, Bohnsack J, Cron RQ, Hashad S, KonÉ-Paut I, et al. Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis. Arthritis Care Res (Hoboken). 2018 Mar;70(3):409–19. | Lire le résumé |
| De Lucia O, Ravagnani V, Pregnolato F, Hila A, Pontikaki I, Gattinara M, et al. Baseline ultrasound examination as possible predictor of relapse in patients affected by juvenile idiopathic arthritis (JIA). Annals of the Rheumatic Diseases. 2018 Feb 6;annrheumdis-2017-211696. | Lire le résumé |
| Bayraktar D, Savci S, Altug-Gucenmez O, Manci E, Makay B, Ilcin N, et al. The effects of 8-week water-running program on exercise capacity in children with juvenile idiopathic arthritis: a controlled trial. Rheumatology International [Internet]. 2018 Nov 14 [cited 2018 Dec 19] | Lire le résumé |
| Hinze CH, Foell D, Johnson AL, Spalding SJ, Gottlieb BS, Morris PW, et al. Serum S100A8/A9 and S100A12 Levels in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis: Relationship to Maintenance of Clinically Inactive Disease During Anti-Tumor Necrosis Factor Therapy and Occurrence of Disease Flare After Discontinu. Arthritis Rheumatol. mars 2019;71(3):451‐9 | Lire le résumé |
| Saccomanno B, Tibaldi J, Minoia F, Bagnasco F, Pistorio A, Guariento A, et al. Predictors of Effectiveness of Anakinra in Systemic Juvenile Idiopathic Arthritis. J Rheumatol. avr 2019;46(4):416‐21 | Lire le résumé |
| Gohar F, McArdle A, Jones M, Callan N, Hernandez B, Kessel C, et al. Molecular signature characterisation of different inflammatory phenotypes of systemic juvenile idiopathic arthritis. Ann Rheum Dis. 20 avr 2019;annrheumdis-2019-215051 | Lire le résumé |
| Kearsley-Fleet L, Sampath S, McCann LJ, Baildam E, Beresford MW, Davies R, et al. Use and effectiveness of rituximab in children and young people with juvenile idiopathic arthritis in a cohort study in the United Kingdom. Rheumatology. 1 févr 2019;58(2):331 5 | Lire le résumé |
| ter Haar NM, Dijkhuizen EHP, Swart JF, Royen‐Kerkhof A, el Idrissi A, Leek AP, et al. Treatment to Target Using Recombinant Interleukin‐1 Receptor Antagonist as First‐Line Monotherapy in New‐Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five‐Year Follow‐Up Study. Arthritis Rheumatol [Internet]. 25 mai 2019 [cité 19 juill 2019]; Disponible sur: https://onlinelibrary.wiley.com/doi/abs/10.1002/art.40865" | Lire le résumé |
| ter Haar NM, Dijkhuizen EHP, Swart JF, Royen‐Kerkhof A, el Idrissi A, Leek AP, et al. Treatment to Target Using Recombinant Interleukin‐1 Receptor Antagonist as First‐Line Monotherapy in New‐Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five‐Year Follow‐Up Study. Arthritis Rheumatol. juill 2019;71(7):1163 73 | Lire le résumé |
| Renton WD, Leveret H, Guly C, Smee H, Leveret J, Ramanan AV. Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritis. Pediatr Rheumatol [Internet]. déc 2019 [cité 21 oct 2019];17(1). | Lire le résumé |
| 1. Schulert GS, Yasin S, Carey B, Chalk C, Do T, Schapiro AH, et al. Systemic Juvenile Idiopathic Arthritis–Associated Lung Disease: Characterization and Risk Factors. Arthritis Rheumatol. nov 2019;71(11):1943 54 2.Saper VE , Chen G, Deutsch GH, Guillerman RP, Birgmeier J, Jagadeesh K, et al. Emergent high fatality lung disease in systemic juvenile arthritis. Ann Rheum Dis. déc 2019;78(12):1722 31 | Lire le résumé |
| Lee PY, Schulert GS, Canna SW, Huang Y, Sundel J, Li Y, et al. Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Ann Rheum Dis. 9 nov 2019;annrheumdis-2019-216030 | Lire le résumé |
| Brunelli JB, Silva CA, Pasoto SG, Saa CGS, Kozu KT, Goldenstein-Schainberg C, et al. Anti-adalimumab antibodies kinetics: an early guide for juvenile idiopathic arthritis (JIA) switching. Clin Rheumatol [Internet]. 9 nov 2019 [cité 17 déc 2019] | Lire le résumé |
| Klein A, Klotsche J, Hügle B, Minden K, Hospach A, Weller-Heinemann F, Schwarz T, Dressler F, Trauzeddel R, Hufnagel M, Foeldvari I, Borte M, Kuemmerle-Deschner J, Brunner J, Oommen PT, Föll D, Tenbrock K, Urban A, Horneff G. Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registry. Rheumatology (Oxford). 2019 Dec 17 | Lire le résumé |
| Zhong L, Wang W, Li J, Ma M, Gou L, Wang C, et al. The association of MEFV gene mutations with the disease risk and severity of systemic juvenile idiopathic arthritis. Pediatr Rheumatol [Internet]. déc 2020 [cité 22 juin 2020];18(1). | Lire le résumé |
| Pawlaczyk-Kamieńska T, Paczyk-Wróblewskawla E, Borysewicz-Lewicka M. Early diagnosis of temporomandibular joint arthritis in children with juvenile idiopathic arthritis. A systematic review. Eur J Paediatr Dent. 2020;21(3):219‑26. | Lire le résumé |
| Quartier P, Alexeeva E, Constantin T, Chasnyk V, Wulffraat N, Palmblad K, et al. Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open‐Label, Randomized Study. Arthritis Rheumatol. févr 2021;73(2):336‑46. | Lire le résumé |
| Nigrovic PA, Colbert RA, Holers VM, Ozen S, Ruperto N, Thompson SD, et al. Biological classification of childhood arthritis: roadmap to a molecular nomenclature. Nat Rev Rheumatol. mai 2021;17(5):257‑69. | Lire le résumé |
| Ruperto N, Brunner HI, Pacheco-Tena C, Louw I, Vega-Cornejo G, Spindler AJ, et al. Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis. Rheumatology. 2 oct 2021;60(10):4495‑507 | Lire le résumé |
| Zheng S, Lee PY, Huang Y, Deng W, Huang Z, Huang Q, et al. Clinical characteristics of juvenile gout and treatment response to febuxostat. Ann Rheum Dis. 20 déc 2021;annrheumdis-2021-221762. | Lire le résumé |
| Ruperto N, Brunner HI, Synoverska O, Ting TV, Mendoza CA, Spindler A, et al. Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. The Lancet. nov 2021;398(10315):1984‑96. | Lire le résumé |
| Zhao Y, Sullivan E, Son MB, Beukelman T. Psoriasis rate is increased by the exposure to TNF inhibition in children with JIA. Ann Rheum Dis. mai 2022;81(5):662‑5. | Lire le résumé |
| Lillemor Berntson, A pilot study of possible anti-inflammatory effects of the specific carbohydrate diet in children with juvenile idiopathic arthritis, Pediatric Rheumatology, https://doi.org/10.1186/s12969-021-00577-3 | Lire le résumé |
| Gerss J, Tedy M, Klein A, Horneff G, Miranda-Garcia M, Kessel C, et al. Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis: results from the PREVENT-JIA trial. Ann Rheum Dis. juill 2022;81(7):990‑7 | Lire le résumé |
| Kittivisuit S, Sripornsawan P, Songthawee N, Chavananon S, McNeil EB, Chotsampancharoen T. Musculoskeletal involvement in childhood leukemia: Characteristics and survival outcomes. Pediatr Rheumatol. déc 2022;20(1):34 | Lire le résumé |
| Pediatric and Pediatric Rheumatology Consultant, East Jeddah Hospital, Jeddah, Saudi Arabia, Bakry R, Klein MA, Medical faculty department of Paediatrics, University of Cologne, Cologne, Germany, Horneff G, Department of General Peadiatric, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, et al. Oral or Parenteral Methotrexate for the Treatment of Polyarticular Juvenile Idiopathic Arthritis. Eur J Rheumatol | Lire le résumé |
| Brunello F, Tirelli F, Pegoraro L, Dell’Apa F, Alfisi A, Calzamatta G, et al. New Insights on Juvenile Psoriatic Arthritis. Front Pediatr. 26 mai 2022;10:884727 | Lire le résumé |
| Fordham NJ, Bartram J, Ghorashian S, O’Connor D, Taylor A, Sibson K, et al. What is the diagnostic yield of bone marrow aspiration to exclude leukaemia prior to systemic treatment in juvenile idiopathic arthritis? Br J Haematol. nov 2022;199(3):447‑51. | Lire le résumé |
| Brunner HI, Foeldvari I, Alexeeva E, Ayaz NA, Calvo Penades I, Kasapcopur O, et al. Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial. Ann Rheum Dis. 12 août 2022;annrheumdis-2022-222849 | Lire le résumé |
| Guo Y, Fang Y, Zhang T, Pan Y, Wang P, Fan Z, et al. Axial involvement in enthesitis-related arthritis: results from a single-center cohort. Pediatr Rheumatol. 6 févr 2023;21(1):13. | Lire le résumé |
| Räsänen K, Markula-Patjas K, Kantanen S, Sipilä K, Lakka TA, Arikoski P, Piippo-Savolainen E. Impaired cardiorespiratory and neuromuscular fitness in children and adolescents with juvenile idiopathic arthritis: a cross-sectional case-control study in the era of biologic drug therapies. Pediatr Rheumatol Online J. 2023 Mar 17;21(1):26. doi: 10.1186/s12969-023-00808-9. PMID: 36932386; PMCID: PMC10022213. | Lire le résumé |
| Ramanan AV, Quartier P, Okamoto N, Foeldvari I, Spindler A, Fingerhutová Š, et al. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial. Lancet Lond Engl. 6 juill 2023;S0140-6736(23)00921-2. | Lire le résumé |
| Kearsley-Fleet L, Baildam E, Beresford MW, Douglas S, Foster HE, Southwood TR, et al. Successful stopping of biologic therapy for remission in children and young people with juvenile idiopathic arthritis. Rheumatol Oxf Engl. 2 mai 2023;62(5):1926‑35. | Lire le résumé |
| Towe C, Grom AA, Schulert GS. Diagnosis and Management of the Systemic Juvenile Idiopathic Arthritis Patient with Emerging Lung Disease. Pediatr Drugs. nov 2023;25(6):649‑58. | Lire le résumé |